PMID

Data

Article Title

Organization

Stimulation of Glucose-Dependent Insulin Secretion by a Potent, Selective sst3 Antagonist.

TBA

Optimization of Preclinical Metabolism for Somatostatin Receptor Subtype 5-Selective Antagonists.

Merck

Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition.

Merck

Discovery of novel 5-oxa-2,6-diazaspiro[3.4]oct-6-ene derivatives as potent, selective, and orally available somatostatin receptor subtype 5 (SSTR5) antagonists for treatment of type 2 diabetes mellitus.

Scohia Pharma

Discovery of novel somatostatin receptor subtype 5 (SSTR5) antagonists: Pharmacological studies and design to improve pharmacokinetic profiles and human Ether-a-go-go-related gene (hERG) inhibition.

Takeda Pharmaceutical